500 UNICORN PARK, WOBURN, MA
Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Igniting a Systemic Immune Response to Cancer with Oncolytic Immunotherapy
Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Provides Update Following Type A Meeting with FDA
Announces Type A Meeting Scheduled with FDA
Financial Results, Press Release
Q3
Q2
Q1
FY 2024
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence